Goldman Sachs
OMED

Goldman Sachs’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Goldman Sachs’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24,200
Closed -$51K – 6030
2018
Q3 		$51K Buy
24,200
+11,801
+95% +$28.3K ﹤0.01% 5291
2018
Q2 		$29K Sell
12,399
-49,812
-80% -$145K ﹤0.01% 5460
2018
Q1 		$198K Buy
62,211
+10,105
+19% +$27.8K ﹤0.01% 5012
2017
Q4 		$214K Buy
52,106
+24,653
+90% +$107K ﹤0.01% 5396
2017
Q3 		$124K Sell
27,453
-142,986
-84% -$579K ﹤0.01% 5977
2017
Q2 		$568K Sell
170,439
-155,991
-48% -$647K ﹤0.01% 4985
2017
Q1 		$3.01M Buy
326,430
+283,558
+661% +$2.49M ﹤0.01% 3367
2016
Q4 		$331K Buy
42,872
+11,386
+36% +$105K ﹤0.01% 5406
2016
Q3 		$360K Buy
31,486
+4,394
+16% +$51.1K ﹤0.01% 5343
2016
Q2 		$334K Sell
27,092
-29,519
-52% -$358K ﹤0.01% 5244
2016
Q1 		$572K Buy
56,611
+42,274
+295% +$496K ﹤0.01% 4617
2015
Q4 		$323K Buy
14,337
+5,440
+61% +$111K ﹤0.01% 5290
2015
Q3 		$148K Buy
+8,897
New +$178K ﹤0.01% 6221
2014
Q2 		– Sell
-14,076
Closed -$474K – 7368
2014
Q1 		$474K Sell
14,076
-12,978
-48% -$437K ﹤0.01% 5333
2013
Q4 		$799K Buy
27,054
+13,595
+101% +$249K ﹤0.01% 4934
2013
Q3 		$206K Buy
+13,459
New +$249K ﹤0.01% 5851

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs's OMED Position: Q4 2018 in Review

Goldman Sachs sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 24,200 shares — an estimated $51K sold.

Goldman Sachs first reported a position in OMED in Q3 2013 and held it in 16 quarters. The position peaked at $3.01M in Q1 2017. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Goldman Sachs reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Goldman Sachs sold 24,200 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $51K.
  • Goldman Sachs first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 16 quarters.
  • Goldman Sachs's OncoMed Pharmaceuticals, Inc. position peaked at $3.01M in Q1 2017.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.